318 results on '"Betticher D"'
Search Results
2. NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma
3. The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
4. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
5. Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
6. Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]
7. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients
8. Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
9. P30.01 Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01)
10. Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial: 143PD
11. 1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20
12. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
13. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)
14. Oncologie : naviguer la pandémie de COVID-19 et garder le cap [Oncology: navigating the COVID-19 Pandemic and Steer the Course]
15. Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)
16. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
17. Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic non-squamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial SAKK 19/05: V449
18. Exonic expression variations of EGFR and KRAS in small bronchoscopic biopsies from patients with advanced nonsmall cell lung cancer treated by combined bevacizumab/erlotinib therapy followed by platinum-based chemotherapy at disease progression: A multicenter phase II trial SAKK19/05: V448
19. NSCLC stage III - a curative disease?: V126
20. CN38 Implementing a nursing symptom self-management intervention: The Symptom Navi Program
21. 1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial
22. LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)
23. Rare case of remission of a patient with small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) stage IV: Case report
24. Adverse events in oncology and haemato-oncology inpatients of Swiss hospitals: A descriptive study
25. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
26. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
27. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)
28. The use of Allelic Expression Differences to Ascertain Functional Polymorphisms Acting in cis: Analysis of MMP1 Transcripts in Normal Lung Tissue
29. Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study
30. Docetaxel für die neoadjuvanten Therapieansätze der frühen Stadien des nicht-kleinzelligen Bronchuskarzinoms
31. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
32. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
33. Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity
34. The effect of Rituximab on patients with follicular and mantle-cell lymphoma
35. The cyclin-dependent kinase inhibitors p18INK4c and p19INK4d are highly expressed in CD34+ progenitor and acute myeloid leukaemic cells but not in normal differentiated myeloid cells
36. Treatment of hairy cell leukemia with cladribine(2-chlorodeoxyadenosine) by subcutaneous bolus injection:a phase II study
37. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenstrom's macroglobulinaemia
38. CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09)
39. MA 15.11 CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09)
40. NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma
41. The Hyperreactive Malarial Splenomegaly Syndrome in a European: Has the Treatment a Modulatory Effect on the Immune System?
42. The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
43. CN31 - Adverse events in oncology and haemato-oncology inpatients of Swiss hospitals: A descriptive study
44. Preoperative chemotherapy and radiotherapy concomitant to cetuximab in stage IIIB NSCLC: A multicenter phase II SAKK
45. Afatinib for patients with advanced NSCLC pretreated with chemotherapy and an EGFR tyrosine kinase inhibitor: Retrospective analysis of the Swiss Afatinib Named Patient Program
46. 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial
47. The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MO AIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
48. Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients
49. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
50. Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.